Bibliographie

1. PORCO TC, MARTIN JN, PAGE-SHAFER KA et al. Decline in HIV infectivity following the introduction
of highly active antiretroviral therapy. AIDS, 2004, 18 : 81-88.
2. YAMASHITA TE, PHAIR JP, MUNOZ A et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS, 2001, 15 : 735-746.
3. MOORE RD, KERULY JC, GEBO KA, LUCAS GM. An improvement in virologic response to highly active antiretroviral therapy in clinical practice from 1996 through 2002. J AIDS, 2005, 39 : 195-198.
4. GARCIA F, DE LAZZARI E, PLANA M et al. Long-term CD4+ T-cell response to highly active antiretroviral
therapy according to baseline CD4+ T-cell count. J AIDS, 2004, 36 : 702-713.
5. HAMMER SM, SQUIRES KE, HUGHES MD et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med, 1997, 337 : 725-733.
6. CAMERON DW, HEATH-CHIOZZI M, DANNER S et al. Randomised placebo-controlled trial of ritonavir
in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet, 1998, 351 : 543-549.
7. LANOY E, MARY-KRAUSE M, TATTEVIN P et al. Frequency, determinants and consequences of delayed access to care for HIV infection in France. Antivir Ther, 2007, 12 : 89-96.
8. EGGER M, MAY M, CHÈNE G et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy : a collaborative analysis of prospective studies. Lancet, 2002, 360 : 119-129.
9. CHÈNE G, STERNE JA, MAY M et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy : analysis of prospective studies. Lancet, 2003, 362 : 679-686.
10. SHELBURNE SA, VISNEGARWALA F, DARCOURT J et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS, 2005, 19 : 399-406.
11. MAY M, STERNE JA, SABIN C et al. Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART : collaborative analysis of prospective studies. AIDS, 2007, 31 : 1185-1197.
12. EL-SADR WM, LUNDGREN JD, NEATON JD et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med, 2006, 355 : 2283-2296.
13. PALELLA FJ, DELORIA-KNOLL M, CHMIEL JS et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med, 2003, 138 : 620-626.
14. MOORE RD, KERULY JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis, 2007, 44 : 441-446.
15. BAKER JV, PENG G, RAPKIN J et al. CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection [in process citation]. AIDS, 2008, 22 : 841-888.
16. BRAITHWAITE RS, ROBERTS MS, CHANG CC et al. Influence of alternative thresholds for initiating HIV treatment on quality-adjusted life expectancy : a decision model. Ann Intern Med, 2008, 148 : 178-185.
17. MOORE D, HOGG R, YIP B et al. Baseline CD4 percentage is predictive of survival in patients starting
antiretroviral therapy, including those with CD4 cell counts between 200 and 350 cells/ml. 12th CROI, Boston, 2005, abstract 589.
18. PHAIR JP, MELLORS JW, DETELS R et al. Virologic and immunologic values allowing safe deferral of antiretroviral therapy. AIDS, 2002, 16 : 2455-2459.
19. WOOD E, HOGG RS, YIP B et al. Higher baseline levels of plasma human immunodeficiency virus type 1 RNA are associated with increased mortality after initiation of triple-drug antiretroviral therapy. J Infect Dis, 2003, 18 : 1421-1425.
20. ATTA MG, GALLANT JE, RAHMAN MH et al. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant, 2006, 21 : 2809-2813.
21. GEBREKRISTOS HT, MLISANA KP, KARIM QA. Patients' readiness to start highly active antiretroviral
treatment for HIV. Br Med J, 2005, 331 : 772-775.
22. WOOD E, HOGG RS, YIP B et al. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 × 10(9) cells/L. Ann Intern Med, 2003, 139 : 810-816.
23. ANASTOS K, BARRON Y, COHEN MH et al. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med, 2004, 140 : 256-264.
24. CARRIERI MP, RAFFI F, LEWDEN C et al. Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response : a 3-year follow-up study. Antivir Ther, 2003, 8 : 585-594.
25. PARSONS JT, ROSOF E, PUNZALAN JC, DI MARIA L. Integration of motivational interviewing and cognitive behavioral therapy to improve HIV medication adherence and reduce substance use among HIV-positive men and women : results of a pilot project. AIDS Patient Care STDs, 2005, 19 : 31-39.
26. COTE JK, GODIN G. Efficacy of interventions in improving adherence to antiretroviral therapy. Int
J STD AIDS, 2005, 16 : 335-343.
27. BANGSBERG DR, ACOSTA EP, GUPTA R et al. Adherence-resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness. AIDS, 2006, 20 : 223-231.
28. GARDNER EM, SHARMA S, PENG G et al. Differential adherence to combination antiretroviral therapy is associated with virological failure with resistance. AIDS, 2008, 22 : 75-82.
29. RIDDLER SA, HAUBRICH R, DI RIENZO AG et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med, 2008, 358 : 2095-2106.
30. VAN LETH F, PHANUPHAK P, RUXRUNGTHAM K et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine : a randomised open-label trial, the 2NN study. Lancet, 2004, 363 : 1253-1263.
31. VAN LETH F, ANDREWS S, GRINSZTEJN B et al. The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS, 2005, 19 : 463-471.
32. ERON J, YENI P, GATHE J et al. The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir,
each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks : a randomised non-inferiority trial. Lancet, 2006, 368 : 476-482.
33. RUANE PJ, LUBER AD, WIRE MB et al. Plasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteers. Antimicrob Agents Chemother, 2007, 51 : 560-565.
34. GALLANT JE, DE JESUS E, ARRIBAS JR et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine,
lamivudine, and efavirenz for HIV. N Engl J Med, 2006, 354 : 251-260.
35. GALLANT JE, STASZEWSKI S, POZNIAK AL et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients : a 3-year randomized trial. JAMA, 2004, 292 : 191-201.
36. ARRIBAS JR, POZNIAK AL, GALLANT JE et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients : 144-week analysis. J AIDS, 2008, 47 : 74-78.
37. DE JESUS E, HERRERA G, TEOFILO E et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults [in process citation]. Clin Infect Dis, 2004, 39 : 1038-1146.
38. MOYLE GJ, DE JESUS E, CAHN P et al. Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults : results of the Ziagen Once Daily in Antiretroviral Combination Study. J AIDS, 2005, 38 : 417-425.
39. MALLAL S, PHILLIPS E, CAROSI G et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med, 2008, 358 : 568-579.
40. SABIN CA, WORM SW, WEBER R et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study : a multi-cohort collaboration [in process citation]. Lancet, 2008, 371 : 1417-1126.
41. ROBBINS GK, DE GRUTTOLA V, SHAFER RW et al. Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med, 2003, 349 : 2293-2303.
42. SAAG MS, CAHN P, RAFFI F et al. Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients : a randomized trial. JAMA, 2004, 292 : 180-189.
43. MOLINA JM, FERCHAL F, RANCINAN C et al. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J Infect Dis, 2000, 182 : 599-602.
44. GULICK RM, RIBAUDO HJ, SHIKUMA CM et al. Triple-nucleoside regimens versus efavirenz-containing
regimens for the initial treatment of HIV-1 infection. N Engl J Med, 2004, 350 : 1850-1861.
45. STASZEWSKI S, KEISER P, MONTANER J et al. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults : a randomized equivalence trial. JAMA, 2001, 285 : 1155-1163.
46. MARKOWITZ M, HILL-ZABALA C, LANG J et al. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients. J AIDS, 2005, 39 : 257-264.
47. ORKIN C, STEBBING J, NELSON M et al. A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study). J Antimicrob Chemother, 2005, 55 : 246-251.
48. GULICK RM, RIBAUDO HJ, SHIKUMA CM et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection : a randomized controlled trial. JAMA, 2006, 296 : 769-781.
49. DUVIVIER C, GHOSN J, ASSOUMOU L et al. Lower rate of virological suppression in naive patients initiating HAART with NRTI-sparing regimen compared to standard NRTI-containing regimen :
results from Hippocampe-ANRS 121 Trial. 10th EACS, Dublin, 2005, abstract PS 1/3.
50. DELFRAISSY JF, FLANDRE P, DELAUGERRE C et al. Lopinavir/ritonavir monotherapy or plus zidovudine
and lamivudine in antiretroviral-naive HIV-infected patients. AIDS, 2008, 22 : 385-393.
51. SHAFER RW, SMEATON LM, ROBBINS GK et al. Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection. N Engl J Med, 2003, 349 : 2304-2315.
52. YENI P, COOPER DA, ABOULKER JP et al. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO : open-label randomised trial. Lancet, 2006, 368 : 287-298.
53. MACARTHUR RD, NOVAK RM, PENG G et al. A comparison of three highly active antiretroviral treatment
strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study) : a long-term randomised trial. Lancet, 2006, 368 : 2125-2135.
54. ARRANZ CASO JA, LOPEZ JC, SANTOS I et al. A randomized controlled trial investigating the efficacy
and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load [in process citation]. HIV Med, 2005, 6 : 353-339.
55. CALZA L, MANFREDI R, COLANGELI V et al. Substitution of nevirapine or efavirenz for protease inhibitor versus lipid-lowering therapy for the management of dyslipidaemia. AIDS, 2005, 19 : 1051-1058.
56. MOLINA JM, JOURNOT V, MORAND-JOUBERT L et al. Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen : a randomized trial. J Infect Dis, 2005, 191 : 830-839.
57. VAN LETH F, PHANUPHAK P, STROES E et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med, 2004, 1 : e19.
58. PARIENTI JJ, MASSARI V, REY D et al. Efavirenz to nevirapine switch in HIV-1-infected patients with dyslipidemia : a randomized, controlled study. Clin Infect Dis, 2007, 49 : 263-266.
59. WIT FW, KESSELRING AM, GRAS L et al. Discontinuation of nevirapine because of hypersensitivity reactions in patients with prior treatment experience, compared with treatment-naive patients : the ATHENA cohort study [in process citation]. Clin Infect Dis, 2008, 46 : 933-940.
60. MOCROFT A, STASZEWSKI S, WEBER R et al. Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts. Antivir Ther, 2007, 12 : 325-333.
61. CLUMECK N, GOEBEL F, ROZENBAUM W et al. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS, 2001, 15 : 1517-1526.
62. BUCHER HC, KOFLER A, NUESCH R et al. Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients. AIDS, 2003, 17 : 2451-2459.
63. BONJOCH A, PAREDES R, GALVEZ J et al. Antiretroviral treatment simplification with 3 NRTIs or 2
NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART. J AIDS, 2005, 39 : 313-316.
64. OPRAVIL M, HIRSCHEL B, LAZZARIN A et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis, 2002, 185 : 1251-1260.
65. MARTINEZ E, ARNAIZ JA, PODZAMCZER D et al. Substitution of nevirapine, efavirenz, or abacavir for
protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med, 2003, 349 : 1036-1046.
66. FISCHL MA, COLLIER AC, MUKHERJEE AL et al. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen. AIDS, 2007, 21 : 325-333.
67. ARRIBAS JR, PULIDO F, DELGADO R et al. Lopinavir/ritonavir as single-drug therapy for maintenance
of HIV-1 viral suppression : 48-week results of a randomized, controlled, open-label, proof-of-concept pilot clinical trial (OK study). J AIDS, 2005, 40 : 280-287.
68. KAHLERT C, HUPFER M, WAGELS T et al. Ritonavir boosted indinavir treatment as a simplified maintenance “mono”-therapy for HIV infection. AIDS, 2004, 18 : 955-957.
69. CAMPO RE, LALANNE R, TANNER TJ et al. Lopinavir/ritonavir maintenance monotherapy after successful
viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients. AIDS, 2005, 19 : 447-449.
70. SWINDELLS S, DIRIENZO G, WILKIN T et al. Regimen simplification to atazanavir/ritonavir alone as
maintenance antiretroviral therapy after sustained virologic suppression (ACTG 5201). JAMA, 2006, 296 : 806-814.
71. KARLSTROM O, JOSEPHSON F, SONNERBORG A. Early virologic rebound in a pilot trial of ritonavir-boosted atazanavir as maintenance monotherapy. J AIDS, 2007, 44 : 417-422.
72. PULIDO F, ARRIBAS JR, DELGADO R et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir
and two nucleosides for maintenance therapy of HIV. AIDS, 2008, 22 : F1-F9.
73. CAMERON DW, DA SILVA BA, ARRIBAS JR et al. A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy
[epub ahead of print] [record supplied by publisher]. J Infect Dis, 2008, 198 : 234-240.
74. GATELL J, SALMON-CERON D, LAZZARIN A et al. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen : the SWAN Study (AI424-097) 48-week results. Clin Infect Dis, 2007, 44 : 1484-1492.
75. SORIANO V, GARCIA-GASCO P, VISPO E et al. Efficacy and safety of replacing lopinavir with atazanavir
in HIV-infected patients with undetectable plasma viraemia : final results of the SLOAT trial. J Antimicrob Chemother, 2008, 61 : 200-205.
76. PIKETTY C, WEISS L, BACHIR-CHERIF S et al. Time to HAART Resume after structured treatment interruption is strongly associated with HIV DNA level in PBMC at interruption : results of the ANRS 116 SALTO trial. 16th International AIDS Conference, Toronto, Canada, 2006.
77. MAGGIOLO F, RIPAMONTI D, GREGIS G et al. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells : a controlled, prospective trial. AIDS, 2004, 18 : 439-446.
78. BOSCHI A, TINELLI C, ORTOLANI P et al. CD4+ cell-count-guided treatment interruptions in chronic HIV-infected patients with good response to highly active antiretroviral therapy. AIDS, 2004, 18 : 2381-2389.
79. MUSSINI C, BEDINI A, BORGHI V et al. CD4 cell-monitored treatment interruption in patients with a
CD4 cell count > ; 500 × 106 cells/l. AIDS, 2005, 19 : 287-294.
80. PELLEGRIN I, THIEBAUT R, BLANCO P et al. Can highly active antiretroviral therapy be interrupted in
patients with sustained moderate HIV RNA and > ; 400 CD4+ cells/microl ? Impact on immunovirological
parameters. J Med Virol, 2005, 77 : 164-172.
81. TOULSON AR, HARRIGAN R, HEATH K et al. Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts > ; 200 cells/mm3. J Infect Dis, 2005, 192 : 1787-1793.
82. ANANWORANICH J, GAYET-AGERON A, LE BRAZ M et al. CD4-guided scheduled treatments interruptions
compared to continuous therapy : results of the Staccato trial. Lancet, 2006, 368 : 459-465.
83. NETTLES RE, KIEFFER TL, KWON P et al. Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART. JAMA, 2005, 293 : 817-829.
84. NEBBIA G, BOOTH C, SMITH C et al. The reproductibility and long-term impact of viral load blips on
virological and immunological outcomes of first-line HAART. 10th European AIDS Conference (EACS), Dublin, 2005, abstract PS 3/5.
85. PODSADECKI TJ, VRIJENS BC, TOUSSET EP et al. Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia. J Infect Dis, 2007, 196 : 1773-1778.
86. JONES LE, PERELSON AS. Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy. J AIDS, 2007, 45 : 483-493.
87. WOOD E, YIP B, HOGG RS et al. Full suppression of viral load is needed to achieve an optimal CD4 cell count response among patients on triple drug antiretroviral therapy. AIDS, 2000, 14 :1955-1960.
88. DEEKS SG, BARBOUR JD, MARTIN JN et al. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis, 2000, 181 : 946-953.
89. LE MOING V, CHÈNE G, LEPORT C et al. Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patients. Clin Infect Dis, 2002, 34 : 239-247.
90. MURRI R, LEPRI AC, CICCONI P et al. Is moderate HIV viremia associated with a higher risk of clinical progression in HIV-infected people treated with highly active antiretroviral therapy : evidence from the Italian cohort of antiretroviral-naive patients study. J AIDS, 2006, 41 : 23-30.
91. DURAN S, SAVES M, SPIRE B et al. Failure to maintain long-term adherence to highly active antiretroviral therapy : the role of lipodystrophy. AIDS, 2001, 15 : 2441-2444.
92. CARRIERI P, CAILLETON V, LE MOING V et al. The dynamic of adherence to highly active antiretroviral
therapy : results from the French National APROCO cohort. J AIDS, 2001, 28 : 232-239.
93. LAWRENCE J, MAYERS DL, HULLSIEK KH et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med, 2003, 349 : 837-846.
94. GHOSN J, WIRDEN M, KTORZA N et al. No benefit of a structured treatment interruption based on
genotypic resistance in heavily pretreated HIV-infected patients. AIDS, 2005, 19: 1643-1647.
95. HAMMER SM, VAIDA F, BENNETT KK et al. Dual vs single protease inhibitor therapy following antiretroviral treatment failure : a randomized trial. JAMA, 2002, 288 : 169-180.
96. BENSON CA, DEEKS SG, BRUN SC et al. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir
plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients. J Infect Dis, 2002, 185 : 599-607.
97. LALEZARI JP, HENRY K, O'HEARN M et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med, 2003, 348 : 2175-2185.
98. LAZZARIN A, CLOTET B, COOPER D et al. Efficacy of enfuvirtide in patients infected with drug-resistant
HIV-1 in Europe and Australia. N Engl J Med, 2003, 348 : 2186-2195.
99. CASTAGNA A, DANISE A, MENZO S et al. Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus : a randomized pilot study (E-184V study) [in process citation]. AIDS, 2006, 20 : 795-303.
100. MOLINA JM, MARCELIN AG, PAVIE J et al. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy : a randomized placebo-controlled trial. J Infect Dis, 2005, 191 : 840-847.
101. LEDERGERBER B, LUNDGREN JD, WALKER AS et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviraldrug classes. Lancet, 2004, 364 : 51-62.